Hypertension is reported to occur in over one-half of cancer patients treated with vascular endothelial growth factor inhibitors due to decreased nitric oxide production and angiogenesis, oxidative stress, impaired natriuresis, endothelin-1-mediated vasoconstriction, and thrombotic microangiopathy.2–5 Alkylating and alkyl-like agents can induce hypertension via vascular endothelial injury and nephrotoxicity.6,7. This evidence concerns the gene EDN1 and hypertensive disorder.